Stock Analiz

Atossa Therapeutics, Inc. ATOS

Biotechnology: Pharmaceutical Preparations · IPO 2012 · data as of November 13, 2026

$1.96Market cap $20M
Open the interactive analysis →

Atossa Therapeutics, Inc. (ATOS) is a healthcare company listed in the US with a market value of about $20M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -41%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Atossa Therapeutics

Atossa Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2012. It was profitable in 0 of the last 10 years in our data. Its share count rose by 2% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-180.4%
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-41.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————————
Net income-$35M-$26M-$30M-$27M-$21M-$18M-$17M-$11M-$8M-$6M
Free cash flow-$30M-$21M-$21M-$21M-$16M-$12M-$9M-$9M——
EPS (diluted)$-4.04$-3.04$-3.60$-3.15$-2.70$-29.55$-30448.74$-82496.59$-164543.20$-388783.83
Net margin——————————
ROIC-94.4%-38.6%-34.5%-23.5%-14.9%-53.7%-130.7%-128.4%-110.2%-203.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Atossa Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Atossa Therapeutics pay a dividend?

Not currently.

Is Atossa Therapeutics a good stock to buy?

We do not give buy or sell advice. Atossa Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.